Skip to main content Help with accessibility Skip to main navigation

Shared-care Guidelines

***PLEASE NOTE: Guidance is being issued by SPS recommending extended monitoring intervals for medication issued under a shared-care agreement during the COVID-19 NHS response - MLCSU reviewed and locally adapted versions of this guidance can be accessed here: MLCSU Central COVID-19 resource page. Please check back regularly for updates***

**Please note — Morecambe Bay CCG have agreed to the Atypical Antipsychotic Shared Care Guidelines for use in patients that fall under LCFT; for patients in South Cumbria the Cumbria Shared Care Guidelines should be followed

**Please note — For Blackpool, Fylde & Wyre CCG DMARD Shared Care Guidelines please use the versions available on the CCG website 

DMARDs Shared Care Agreement (Version 1.1)

Not adopted
Not adopted
Adopted
Not adopted
Not adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018

Rheumatoid arthritis, severe psoriasis, severe active juvenile idiopathic
arthritis, severe psoriatic arthritis, mild to moderate Crohn’s disease
Unlicensed: Severe Eczema, Lichen Planus, Felty’s syndrome, severe Crohn’s disease

N.B. Not all brands/formulations are licensed for all indications – please refer to individual SPCs

Not adopted
Not adopted
Adopted
Not adopted
Not adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2018

This protocol only applies to the unlicensed indications listed below. Transplant protocols should be followed for licensed indications.

Unlicensed: Severe rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, connective tissue diseases with severe / organ-threatening manifestations, interstitial lung disease (not to be used in idiopathic pulmonary fibrosis IPF), vasculitidies, as maintenance post cyclophosphamide in patients for whom azathioprine is contra-indicated or is inappropriate.